drugset

drugset / Trial / NCT01175590

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

NCT01175590 ↗

Phase 3 Completed 518 enrolled Bausch & Lomb Incorporated

RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.

Timeline

Start: 2010-06
Primary completion: 2011-12
Completion: 2012-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Besifloxacin	Small molecule	0.6 %	Other

Indications